ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

ClinicalTrials.gov ID: NCT05941520

Public ClinicalTrials.gov record NCT05941520. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer

Study identification

NCT ID
NCT05941520
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
80 participants

Conditions and interventions

Interventions

  • Acolbifene Hydrochloride Drug
  • Biospecimen Collection Procedure
  • Mammography Procedure
  • Questionnaire Administration Other
  • Random Periareolar Fine-Needle Aspiration Procedure
  • Tamoxifen Drug

Drug · Procedure · Other

Eligibility (public fields only)

Age range
35 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 22, 2024
Primary completion
Aug 22, 2027
Completion
Aug 31, 2028
Last update posted
May 12, 2026

2024 – 2028

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
City of Hope Comprehensive Cancer Center Duarte California 91010 Recruiting
Northwestern University Chicago Illinois 60611 Recruiting
University of Kansas Cancer Center Kansas City Kansas 66160 Recruiting
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05941520, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 12, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05941520 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →